Reduction of concurrent use of highly… | 2023

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

33/100

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

Being in the top 5% indicates that 95% of all other Medicare Advantage plans prescribed more Poly-ACH regimens than KPSC. However, the CMS measure focuses on the percentage of older adults taking at least one ACH drug (i.e., denominator) who meet Poly-ACH criteria (i.e., numerator), rather than ensuring that the annual percent decline was not simply due to an increase in the denominator. 5.63% of patients received Poly-ACH agents in 2018 compared with 4.42% in 2019, 4.28% in 2020, and 3.79% in 2021. Significantly, in 2019, there were 6448 fewer older patients on at least one ACH drug (ie denominator) compared with 2018, and 1720 fewer patients in 2020 compared with 2019, and 1215 fewer patients in 2021 compared with 2020.

What this study adds

Evidence grade: Low

This report describes a decline in the concurrent prescribing of highly anticholinergic medications to older adults in one healthcare system. Reported effect size: 5.63%; 4.42%; 4.28%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lee, E. A., Steinberg, S. G., Cheng, S. C., Lieu, W. L., Yoshinaga, M. A., Powers, D. C., et al. (2023). Reduction of concurrent use of highly anticholinergic medications in an integrated healthcare system: 2018–2021. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.18604

Vancouver

Lee EA, Steinberg SG, Cheng SC, Lieu WL, Yoshinaga MA, Powers DC, et al. Reduction of concurrent use of highly anticholinergic medications in an integrated healthcare system: 2018–2021. Journal of the American Geriatrics Society. 2023. doi:10.1111/jgs.18604. PMID: 37737472.

BibTeX

@article{lee2023-37737472,
  author  = {Lee, Eric A. and Steinberg, Steven G. and Cheng, Stephen C. and Lieu, William L. and Yoshinaga, Monica A. and Powers, Daniel C. and Kanter, Michael H. and Broder, Benjamin I.},
  title   = {{Reduction of concurrent use of highly anticholinergic medications in an integrated healthcare system: 2018–2021}},
  journal = {Journal of the American Geriatrics Society},
  year    = {2023},
  doi     = {10.1111/jgs.18604},
  pmid    = {37737472},
  url     = {https://doi.org/10.1111/jgs.18604}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record reports “5.63%; 4.42%; 4.28%”. A statistically significant result can still be small in daily life.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Being in the top 5% indicates that 95% of all other Medicare Advantage plans prescribed more Poly-ACH regimens than KPSC.
However, the CMS measure focuses on the percentage of older adults taking at least one ACH drug (i.e., denominator) who meet Poly-ACH criteria (i.e., numerator), rather than ensuring that the annual percent decline was not simply due to an increase in the denominator. 5.63% of patients received Poly-ACH agents in 2018 compared with 4.42% in 2019, 4.28% in 2020, and 3.79% in 2021.
Significantly, in 2019, there were 6448 fewer older patients on at least one ACH drug (ie denominator) compared with 2018, and 1720 fewer patients in 2020 compared with 2019, and 1215 fewer patients in 2021 compared with 2020.

Why it matters

This report describes a decline in the concurrent prescribing of highly anticholinergic medications to older adults in one healthcare system. It does not address treating, curing, or preventing Alzheimer's disease.

Study details

Effect size5.63%; 4.42%; 4.28%
Evidence strengthLow

How this study scored 33/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society)
Journal's citation record	3 / 4	Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2023 — within 6 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.2 citations a year over 5 year(s) since 2023
Impact for its field and year	1 / 6	Cited 0.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Benjamin I. Broder: h-index 7 (OpenAlex, whole career)
Institution's track record	1 / 3	Kaiser Permanente: institution h-index 732 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 37737472)
Free to read	0 / 2	Behind a paywall — scores zero
Total	33 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Health systems and care delivery from nearby years

Also in Health systems and care delivery

172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →